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functional symptomatology and quality of life. This involved
self-questionnaires, which included the Menopause Rating Scale
(MRS), the Epworth scale, the Short Form 12 (SF12) and the
Centre for Epidemiologic Studies Depression Scale (CES-D),
being ﬁlled out at D0 by the investigator, the patient and her
spouse, then at D56 by the patient and her spouse only.
RESULTS: Upon inclusion, the average age of patients was 54.8
years, with an average BMI of 24.1. Their most recent menstrua-
tions were an average of 4.1 years ago, and they complained of
hot ﬂushes, joint pain and sleep difﬁculties. After 56 days of
treatment with Soy+Mag, a statistically signiﬁcant decrease in
hot ﬂushes was observed (the most frequently found symptom
upon inclusion), along with a statistically signiﬁcant improve-
ment in global, somatic and psychological symptomatology
linked to menopause, and a statistically signiﬁcant improvement
in the patients’ quality of life from a psychological standpoint.
These complaints and their improvement were also clearly iden-
tiﬁed by the investigator and the spouse, though with a differing
intensity that could explain the lack of improvement in quality of
life of the spouse, despite the beneﬁts perceived by his wife.
CONCLUSIONS: The interest in Soy+Mag in treating the func-
tional symptoms of menopausal patients is conﬁrmed by the
statistically signiﬁcant improvement in hot ﬂushes and psycho-
logical symptoms. This study has shown that treatment of the
functional and psychological symptoms of menopausal patients
can be noticeably improved by using soy isoﬂavones.
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OBJECTIVES: Assisted reproductive technologies (ART) are fre-
quently targeted for budget cuts and rationing because infertility
is often considered a low priority. Treatments options are varied
where in-vitro fertilization (IVF) and intracytoplasmic sperm
injection (ICSI) are some of the more interventional and expen-
sive methods. In 2003, in an effort to control expenditure, the
German health authorities decreased funding for ART which
increased costs faced by consumers for IVF and ICSI from €0 to
€1500 and €2000 per cycle, respectively. Based on increased costs
to consumers we estimated the price-elasticity of demand for
fertility services in Germany. METHODS: IVF and ICSI cycle
data was obtained from the Deutsches IVF Register ﬁve years
prior, and one year following implementation of the funding
change. Because demand surged in the year prior to the new
policy, demand was based on the average ﬁve-year change in
cycles as well as the demand one year prior to funding cuts. The
arc-price elasticity of demand method was used to derive elas-
ticities. The cross-price elasticity of clomifene was also evaluated
to assess whether substitution with this low cost treatment
occurred resulting from increased IVF and ICSI costs. RESULTS:
The average annual growth rate for IVF and ICSI cycles during
the ﬁve-year period prior to the policy change was 8% and 30%,
respectively. Growth rates the year prior to the policy change
were 17% and 36% for IVF and ICSI, respectively. Based on the
averaged ﬁve-year change prior to the policy change we estimate
price-elasticities one year after the policy for IVF and ICSI of
0.38 and 0.09, respectively. The price elasticity based on 1-year
change in demand for IVF and ICSI was 0.41 and 0.34, respec-
tively. The cross-price elasticity for clomifene was 0.01 suggest-
ing demand was independent of IVF and ICSI. CONCLUSIONS:
The price elasticity ratios suggest demand for IVF and ICSI in
Germany is relatively inelastic i.e., demand is not associated
closely with price changes. This ﬁnding may be regarded as
contrary to the 50% reduction in IVF/ICSI cycles observed sug-
gesting demand is price sensitive. This can be explained by a
much larger percentage increase in price than the percentage
reduction in services demanded. If demand for IVF/ICSI were
elastic (i.e., elasticity >1.0) the reduction in cycles would have
been much larger. The near zero cross-price elasticity for clo-
mifene suggests demand is independent of IVF/ICSI. These ﬁnd-
ings can help policy makers estimate the consequences of
increasing patient co-payments for ART in the future.
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OBJECTIVES: Polypharmacy in elderly patients has grown in
the last decade giving place to new therapeutic and economic
challenges. The aim of this study was to characterize the nature
of polypharmacy and to identify associated direct drug costs.
METHODS: A community pharmacy based cross-sectional
study was carried out using the brown-bag review methodology.
Elderly patients (65 years old) currently taking 4 or more
drugs were invited to participate in the study. Drugs were clas-
siﬁed using ATC codes and costs were identiﬁed as the retail
prices. SAS Guide version 4.0 was used for statistical analysis,
95% conﬁdence intervals for the average costs per patient and
Mann-Whitney Wilcoxon test to identify differences between
expenditure patterns were used. RESULTS: A total of 1597
patients (66% women, mean age 74.5  6.4 years) were
recruited in 158 pharmacies. Average medicines consumption
was found to be 7.6 per patient. Mean daily cost per patient was
€3.2 (CI 95%: 3.1–3.3). Differences in costs according to age,
gender, educational level or residential area were not statistically
signiﬁcant. Sinvastatin, omeprazol and clopidogrel were identi-
ﬁed as the most costly drugs. CONCLUSIONS: Polypharmacy
was found to be highly prevalente amongst Portuguese elderly
population. Associated direct daily drug costs in these patients
were found to be three times higher when compared to the
general population.
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OBJECTIVES: The aim of this study was to assess the self-
reported clinical practice of physicians, when assessing a patient
presenting with ED for the ﬁrst time and to understand physi-
cian’s and sex therapist’s views on current ED management.
METHODS: The study was conducted during the 2008 annual
congress of the European Association of Urology (EAU). Del-
egates visiting the Pﬁzer exhibition booth were requested to
complete an electronic survey consisting of six closed questions.
Respondents, who were physicians/sex therapists, were selected
for analysis. In addition to demographics, the questions
addressed average frequency of seeing new ED patients/month,
iterative actions taken when an ED patient presented for the ﬁrst
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